DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Public ClinicalTrials.gov record NCT07472517. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer
Study identification
- NCT ID
- NCT07472517
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 670 participants
Conditions and interventions
Interventions
- atezolizumab Drug
- carboplatin Drug
- etoposide Drug
- obrixtamig Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 12, 2026
- Primary completion
- Sep 8, 2028
- Completion
- Jul 29, 2029
- Last update posted
- Apr 27, 2026
2026 – 2029
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Infirmary Cancer Care | Mobile | Alabama | 36607 | Not yet recruiting |
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | Not yet recruiting |
| Bioresearch Partner - Hialeah Hospital | Hialeah | Florida | 33013 | Not yet recruiting |
| Emory University | Atlanta | Georgia | 30322 | Not yet recruiting |
| Norton Cancer Institute, Downtown | Louisville | Kentucky | 40202 | Not yet recruiting |
| University of Maryland School of Medicine | Baltimore | Maryland | 21201 | Not yet recruiting |
| Veterans Affairs Ann Arbor Healthcare System | Ann Arbor | Michigan | 48105 | Not yet recruiting |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | Not yet recruiting |
| AHN Cancer Institute - Allegheny General | Pittsburgh | Pennsylvania | 15212 | Not yet recruiting |
| Baptist Cancer Center - Memphis | Memphis | Tennessee | 38120 | Not yet recruiting |
| University of Wisconsin | Madison | Wisconsin | 53792 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 221 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07472517, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07472517 live on ClinicalTrials.gov.